drugset

drugset / Trial / NCT00391248

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

NCT00391248 ↗

Phase 2 Completed 40 enrolled Ontario Clinical Oncology Group (OCOG) Roche Pharma AG · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To improve the clinical outcomes of patients with non-small cell lung cancer treated with radiation therapy.

Timeline

Start: 2006-11
Primary completion: 2012-12
Completion: 2012-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	—

Indications